PRESS RELEASE For immediate release Devonian Health Group provides more details on Previously Announced Positive Topline Results from Phase 2 Clinical trial of Thykamine™ in Adult Population with Mild-to-Moderate Atopic Dermatitis and the Grant of Stock Options....
Press Releases
DEVONIAN ANNOUNCES THE ISSUANCE OF UNITS IN SETTLEMENT OF INTERESTS OWED TO DEBENTURE HOLDERS
PRESS RELEASE For immediate release DEVONIAN ANNOUNCES THE ISSUANCE OF UNITS IN SETTLEMENT OF INTERESTS OWED TO DEBENTURE HOLDERS. QUEBEC, March 5, 2021 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical...
Devonian Health Group Announces Positive Topline Results from Phase 2 Clinical trial of Thykamine™ in Adult Patients with Mild-to-Moderate Atopic Dermatitis
PRESS RELEASE For immediate release Devonian Health Group Announces Positive Topline Results from Phase 2 Clinical trial of Thykamine™ in Adult Patients with Mild-to-Moderate Atopic Dermatitis. Thykamine™ monotherapy achieved positive results by reaching the...
Devonian Health Group Announces voting results of the Annual General and Special Meeting
PRESS RELEASE For immediate release Devonian Health Group Announces voting results of the Annual General and Special Meeting. QUEBEC, – January 28, 2021 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical...
DEVONIAN ANNOUNCES THE ISSUANCE OF UNITS IN SETTLEMENT OF INTERESTS OWED TO A DEBENTURE HOLDER
PRESS RELEASE For immediate release DEVONIAN ANNOUNCES THE ISSUANCE OF UNITS IN SETTLEMENT OF INTERESTS OWED TO A DEBENTURE HOLDER. QUEBEC, January 22, 2021 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical...